Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646333 | 0.99 | KCNH2 (0.47) | SLC6A3KCNH2LMNACYP1A2CYP3A4 | |
| SCHEMBL2646335 | 0.99 | KCNH2 (0.47) | SLC6A3KCNH2LMNACYP1A2CYP3A4 | |
| SCHEMBL2646064 | 0.88 | KCNH2 (0.46) | SLC6A3KCNH2LMNACYP1A2CYP3A4 | |
| SCHEMBL2662652 | 0.87 | KCNH2 (0.46) | SLC6A3KCNH2LMNACYP1A2CYP3A4 | |
| SCHEMBL2645894 | 0.87 | KCNH2 (0.46) | SLC6A3KCNH2LMNACYP1A2CYP3A4 | |
| SCHEMBL2645899 | 0.87 | KCNH2 (0.46) | SLC6A3KCNH2LMNACYP1A2CYP3A4 | |
| SCHEMBL2644835 | 0.86 | KCNH2 (0.64) | KCNH2LMNA | |
| SCHEMBL2645126 | 0.86 | KCNH2 (0.64) | KCNH2LMNA | |
| SCHEMBL2662375 | 0.86 | KCNH2 (0.64) | KCNH2LMNA | |
| SCHEMBL2648622 | 0.86 | SLC6A3 (0.48) | SLC6A3KCNH2LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | claimed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | claimed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | claimed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | claimed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6528543-B1 | Glucokinase activating for treating type II diabetes; acylurea compound, phenylacetyl-substituted; 1-(2-(3-chloro-phenyl)-3cyclopentyl-propionyl)-3-methyl-urea | HOFFMAN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |